Cholesterol screening and statin use in children: a literature review
| Autor: | Ophelia Blake, Alan P. Macken, Clodagh S. O'Gorman, Karen King |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Statin medicine.drug_class Hypercholesterolemia Hyperlipidemias Disease 030204 cardiovascular system & hematology Pediatrics Coronary artery disease 03 medical and health sciences 0302 clinical medicine Internal medicine Hyperlipidemia medicine Humans Mass Screening cardiovascular diseases 030212 general & internal medicine Myocardial infarction Risk factor Child Mass screening Vascular disease business.industry Anticholesteremic Agents nutritional and metabolic diseases General Medicine medicine.disease Atherosclerosis Lipids Primary Prevention Cardiovascular Diseases Practice Guidelines as Topic lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
| Zdroj: | Irish journal of medical science. 188(1) |
| ISSN: | 1863-4362 |
| Popis: | Atherosclerosis begins in childhood. Fatty streaks, the earliest precursor of atherosclerotic lesions, have been found in the coronary arteries of children of 2 years of age. Hypercholesterolaemia is a risk factor for coronary artery disease. Hypercholesterolaemia can be either primary, when it is characteristic of the main disease, or secondary when it occurs as a result of either a disease process or drug treatment. Given the risk of vascular disease, including myocardial infarction (MI), cerebrovascular accidents (CVA, also known as strokes), peripheral vascular disease (PVD) and ruptured aortic aneurysm, which may follow atherosclerosis, it is important to prevent or slow the early development of atherosclerotic lesions. This prevention necessitates the control of key risk factors such hypercholesterolaemia, dyslipidaemia, hypertension etc. However, at what point this prevention ought to occur, and in what form, is uncertain. Using pharmacological primary prevention for hypercholesterolaemia in the paediatric population is controversial. In an adult patient, hypercholesterolaemia warrants the initiation of a statin. Statins, also known as hydroxymethylglutaryl co-enzyme A inhibitors (or HMG-CoA inhibitors) act by altering cholesterol metabolism. In the paediatric population, the clinical course of vascular disease and the effect of altering this clinical course are less certain. This article reviews the published literature on hypercholesterolaemia in children and the use of statins as a treatment for dyslipidaemia in children. The US National Cholesterol Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents 2012 guidelines (NCEP guidelines) regarding the recognition and treatment of childhood dyslipidaemia are reviewed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink